Personnel Information

写真a

DEGUCHI Sayaka


Job title

Junior Associate Professor
To the head of this page.▲

Campus Career 【 display / non-display 】

  • 2025.04
    -
    Now
    Institute of Science Tokyo， -， Institute of Integrated Research， -， Department of Synthetic Human Body System， Junior Associate Professor
To the head of this page.▲

Research Areas 【 display / non-display 】

  • Biomedical engineering

To the head of this page.▲
 

Published Papers & Misc 【 display / non-display 】

  1. Hiroki Futatsusako, Sayaka Deguchi, Kaori Kosugi, Rina Hashimoto, Noriyo Nagata, Tadaki Suzuki, Takuya Yamamoto, Kazuo Takayama. Modeling human enterovirus A71 infection using an intestinal microphysiological system. Journal of Virology. 2026.05; 100 (5): e0025026. ( PubMed, DOI )

  2. Shuhei Tsujino, Masumi Tsuda, Sayaka Deguchi, Jumpei Ito, Taha Y Taha, Hesham Nasser, Lei Wang, Julia Rosecrans, Rigel Suzuki, Saori Suzuki, Kumiko Yoshimatsu, Melanie Ott, Terumasa Ikeda, Kei Sato, Kazuo Takayama, Shinya Tanaka, Tomokazu Tamura, Takasuke Fukuhara, . A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity. Nature Communications. 2025.12; 17 (1): 735. ( PubMed, DOI )

  3. Ryosuke Negoro, Sayaka Deguchi, Daiju Yamazaki, Kazuo Takayama, Takuya Fujita. Genome edited intestine liver on a chip system for integrated intestinal hepatic drug absorption and metabolism evaluation. Scientific Reports. 2025.11; 15 (1): 38609. ( PubMed, DOI )

  4. Yokoi F, Deguchi S, Takayama K. Advancing intestinal disease research using gut-on-a-chip. Regenerative therapy. 2025.06; 29 541-550. ( PubMed, DOI )

  5. Organoids and microphysiological systems for pharmaceutical research of viral respiratory infections. 2024.11; 60 101041. ( PubMed, DOI )

  6. Polysaccharide-Based Coacervate Microgel Bearing Cationic Peptides That Achieve Dynamic Cell-Membrane Structure Alteration and Facile Cytosolic Infusion of IgGs. 2024.11; ( PubMed, DOI )

  7. Establishment of an ulcerative colitis model using colon organoids derived from human induced pluripotent stem cells. 2024.10; 27 (10): 111049. ( PubMed, DOI )

  8. Construction of multilayered small intestine-like tissue by reproducing interstitial flow. 2024.07; ( PubMed, DOI )

  9. Virological characteristics of the SARS-CoV-2 Omicron EG.5.1 variant. 2024.07; ( PubMed, DOI )

  10. Perfluoropolyether-Based Gut-Liver-on-a-Chip for the Evaluation of First-Pass Metabolism and Oral Bioavailability of Drugs. 2024.07; 10 (7): 4635-4644. ( PubMed, DOI )

  11. Virological characteristics of a SARS-CoV-2-related bat coronavirus, BANAL-20-236. 2024.06; 104 105181. ( PubMed, DOI )

  12. A general fluorescence off/on strategy for fluorogenic probes: Steric repulsion-induced twisted intramolecular charge transfer (sr-TICT). 2024.02; 10 (7): eadi8847. ( PubMed, DOI )

  13. Virological characteristics of the SARS-CoV-2 Omicron XBB.1.5 variant. 2024.02; 15 (1): 1176. ( PubMed, DOI )

  14. Virological characteristics of the SARS-CoV-2 BA.2.86 variant. 2024.02; 32 (2): 170-180. ( PubMed, DOI )

  15. SARS-CoV-2-induced disruption of a vascular bed in a microphysiological system caused by type-I interferon from bronchial organoids. 2024.01; ( PubMed, DOI )

  16. Refining Hepatocyte Models to Capture the Impact of CYP2D6*10 Utilizing a PITCh System. 2024; 47 (8): 1422-1428. ( PubMed, DOI )

  17. Kawakami, E; Saiki, N; Yoneyama, Y; Moriya, C; Maezawa, M; Kawamura, S; Kinebuchi, A; Kono, T; Funata, M; Sakoda, A; Kondo, S; Ebihara, T; Matsumoto, H; Togami, Y; Ogura, H; Sugihara, F; Okuzaki, D; Kojima, T; Deguchi, S; Vallee, S; Mcquade, S; Islam, R; Natarajan, M; Ishigaki, H; Nakayama, M; Nguyen, CT; Kitagawa, Y; Wu, YH; Mori, K; Hishiki, T; Takasaki, T; Itoh, Y; Takayama, K; Nio, Y; Takebe, T. Complement factor D targeting protects endotheliopathy in organoid and monkey models of COVID-19 CELL STEM CELL. 2023.10; 30 (10): 1315-+. ( PubMed, DOI )

  18. Multiple mutations of SARS-CoV-2 Omicron BA.2 variant orchestrate its virological characteristics. 2023.10; e0101123. ( PubMed, DOI )

  19. Ito, J; Suzuki, R; Uriu, K; Itakura, Y; Zahradnik, J; Kimura, KT; Deguchi, S; Wang, L; Lytras, S; Tamura, T; Kida, I; Nasser, H; Shofa, M; Begum, MM; Tsuda, M; Oda, Y; Suzuki, T; Sasaki, J; Sasaki-Tabata, K; Fujita, S; Yoshimatsu, K; Ito, H; Nao, N; Asakura, H; Nagashima, M; Sadamasu, K; Yoshimura, K; Yamamoto, Y; Nagamoto, T; Kuramochi, J; Schreiber, G; Saito, A; Matsuno, K; Takayama, K; Hashiguchi, T; Tanaka, S; Fukuhara, T; Ikeda, T; Sato, K; Suzuki, S; Kato, M; Ferdous, Z; Mouri, H; Shishido, K; Misawa, N; Kimura, I; Kosugi, Y; Lin, P; Suganami, M; Chiba, M; Yoshimura, R; Yasuda, K; Iida, K; Ohsumi, N; Strange, AP; Sauter, D; Nakagawa, S; Wu, JQ; Watanabe, Y; Sakamoto, A; Yasuhara, N; Nakajima, Y; Yajima, H; Shirakawa, K; Takaori-Kondo, A; Nagata, K; Kazuma, Y; Nomura, R; Horisawa, Y; Tashiro, Y; Kawa, Y; Irie, T; Kawabata, R; Shimizu, R; Takahashi, O; Ichihara, K; Motozono, C; Toyoda, M; Ueno, T; Shibatani, Y; Nishiuchi, T. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant NATURE COMMUNICATIONS. 2023.05; 14 (1): 2671. ( PubMed, DOI )

  20. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. 2023.05; 14 (1): 2800. ( PubMed, DOI )

  21. Organ-on-a-chip models for elucidating the cellular biology of infectious diseases. 2023.05; 119504. ( PubMed, DOI )

  22. Elucidation of the liver pathophysiology of COVID-19 patients using liver-on-a-chips. 2023.03; 2 (3): pgad029. ( PubMed, DOI )

  23. State-of-the-art liver disease research using liver-on-a-chip. 2022.12; 42 (1): 62. ( PubMed, DOI )

  24. Application of perfluoropolyether elastomers in microfluidic drug metabolism assays. 2022.11; 627 122253. ( PubMed, DOI )

  25. SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression. 2022.09; 8 (38): eabo6783. ( PubMed, DOI )

  26. Saito, A; Tamura, T; Zahradnik, J; Deguchi, S; Tabata, K; Anraku, Y; Kimura, I; Ito, J; Yamasoba, D; Nasser, H; Toyoda, M; Nagata, K; Uriu, K; Kosugi, Y; Fujita, S; Shofa, M; Begum, MM; Shimizu, R; Oda, Y; Suzuki, R; Ito, H; Nao, N; Wang, L; Tsuda, M; Yoshimatsu, K; Kuramochi, J; Kita, S; Sasaki-Tabata, K; Fukuhara, H; Maenaka, K; Yamamoto, Y; Nagamoto, T; Asakura, H; Nagashima, M; Sadamasu, K; Yoshimura, K; Ueno, T; Schreiber, G; Takaori-Kondo, A; Shirakawa, K; Sawa, H; Irie, T; Hashiguchi, T; Takayama, K; Matsuno, K; Tanaka, S; Ikeda, T; Fukuhara, T; Sato, K. Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant CELL HOST & MICROBE. 2022.09; 30 (9): 1540-+. ( PubMed, DOI )

  27. Generation of HepG2 Cells with High Expression of Multiple Drug-Metabolizing Enzymes for Drug Discovery Research Using a PITCh System. 2022.05; 11 (10): ( PubMed, DOI )

  28. Dual inhibition of TMPRSS2 and Cathepsin Bprevents SARS-CoV-2 infection in iPS cells. 2021.12; 26 1107-1114. ( PubMed, DOI )

  29. SARS-CoV-2 research using human pluripotent stem cells and organoids. 2021.11; 10 (11): 1491-1499. ( PubMed, DOI )

  30. Generation of Tetrafluoroethylene-Propylene Elastomer-Based Microfluidic Devices for Drug Toxicity and Metabolism Studies. 2021.09; 6 (38): 24859-24865. ( PubMed, DOI )

  31. In Vitro Model for a Drug Assessment of Cytochrome P450 Family 3 Subfamily A Member 4 Substrates Using Human Induced Pluripotent Stem Cells and Genome Editing Technology. 2021.08; 5 (8): 1385-1399. ( PubMed, DOI )

  32. Usability of Polydimethylsiloxane-Based Microfluidic Devices in Pharmaceutical Research Using Human Hepatocytes. 2021.08; 7 (8): 3648-3657. ( PubMed, DOI )

  33. Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells. 2021.05; 24 (5): 102428. ( PubMed, DOI )

  34. Establishment of MDR1-knockout human induced pluripotent stem cell line. 2020.06; 35 (3): 288-296. ( PubMed, DOI )

  35. Establishment of SLC15A1/PEPT1-Knockout Human-Induced Pluripotent Stem Cell Line for Intestinal Drug Absorption Studies. 2020.06; 17 49-57. ( PubMed, DOI )

  36. Tolloid-Like 1 Negatively Regulates Hepatic Differentiation of Human Induced Pluripotent Stem Cells Through Transforming Growth Factor Beta Signaling. 2020.02; 4 (2): 255-267. ( PubMed, DOI )

  37. Comparison of commercially available media for hepatic differentiation and hepatocyte maintenance. 2020; 15 (2): e0229654. ( PubMed, DOI )

  38. Generation of Human Induced Pluripotent Stem Cell-Derived Hepatocyte-Like Cells for Cellular Medicine. 2020; 43 (4): 608-615. ( PubMed, DOI )

  39. Modeling of Hepatic Drug Metabolism and Responses in CYP2C19 Poor Metabolizer Using Genetically Manipulated Human iPS cells. 2019.06; 47 (6): 632-638. ( PubMed, DOI )

▼display all

To the head of this page.▲

Conference Activities & Talks 【 display / non-display 】

  1. Sayaka Deguchi. Regulating Intestinal and Hepatic Differentiation with Physiological Fluid Flow. ISSCR 2026 Annual Meeting 2026.07.08

  2. 出口清香,高山和雄. 臓器チップ技術を基盤とした腸管組織の構築および疾患研究への応用. 第103回日本生理学会大会 2026.03.10

  3. Sayaka Deguchi. Generation of a micro-intestine system by reproducing interstitial flow and its application in viral infectious disease. Women and Future in Science Seminar 2025.04.21

  4. 出口清香. MPS技術の活用による粘液層を持つ小腸モデルの開発. 日本動物実験代替法学会 第37回大会 2024.12.01

  5. 出口清香, 武石直樹, 渡邉幸夫, 根来亮介, 岩崎未央, 山本拓也, 川口義弥, 鳥澤勇介, 高山和雄. 間質流の再現によるオンチップでの小腸組織構造の構築. 第23回日本再生医療学会総会 2024.03.21

To the head of this page.▲